History of Rheumatology as a Medical Specialty

Rheumatology emerged as a formally recognized medical specialty during the twentieth century, though the diseases it addresses have afflicted human populations throughout recorded history. This page traces the development of rheumatology from early clinical observations through the establishment of dedicated training pathways, professional societies, and regulatory frameworks. Understanding this history clarifies why the specialty is structured the way it is — and why board certification, fellowship training, and subspecialty classification exist in their present forms.

Definition and scope

Rheumatology is the branch of internal medicine concerned with the diagnosis and management of diseases affecting the joints, muscles, bones, and connective tissues, with particular emphasis on autoimmune and inflammatory conditions. The specialty's scope expanded considerably after the mid-twentieth century as immunology matured as a scientific discipline. The American College of Rheumatology (ACR), founded in 1934 as the American Committee for the Control of Rheumatism, is the primary professional body in the United States that defines scope-of-practice standards, issues classification criteria for diseases, and publishes treatment guidelines.

The full landscape of what rheumatology encompasses today includes more than 100 distinct conditions, ranging from rheumatoid arthritis and lupus to gout, vasculitis, and scleroderma. The ACR's classification criteria — periodically revised with collaboration from the European Alliance of Associations for Rheumatology (EULAR) — serve as the definitional boundaries that distinguish rheumatic disease from orthopedic, neurological, or other systemic conditions.

The specialty's regulatory and credentialing context is governed at the federal level through the American Board of Internal Medicine (ABIM), which administers the rheumatology subspecialty certification examination. The regulatory context for rheumatology includes FDA oversight of biologic therapies and disease-modifying drugs that are central to rheumatologic practice.

How it works

The development of rheumatology as a structured discipline followed a series of discrete phases:

Pre-specialty era (before 1930): Conditions such as gout and arthritis were documented in ancient Egyptian and Greek medical texts. Thomas Sydenham's seventeenth-century clinical descriptions of gout and Alfred Garrod's 1848 identification of elevated uric acid in gout patients established early biochemical frameworks. These observations existed within general medicine without a specialty infrastructure.
Institutionalization (1930s–1950s): The ACR's founding in 1934 marked the first formal professional infrastructure for rheumatology in the United States. Philip Showalter Hench and Edward Calvin Kendall's 1948 demonstration of cortisone's anti-inflammatory effects — work that earned the 1950 Nobel Prize in Physiology or Medicine — created the first disease-modifying pharmacological tool for rheumatic conditions and elevated the specialty's clinical standing.
Immunological integration (1960s–1980s): The discovery of antinuclear antibodies (ANA) and rheumatoid factor (RF) as diagnostic markers, along with the characterization of HLA-B27 as a genetic risk factor for ankylosing spondylitis in 1973, transformed rheumatology into a subspecialty grounded in laboratory immunology. The ABIM formally recognized rheumatology as a subspecialty of internal medicine in 1972, establishing the first board certification examination.
Biologic era (1990s–present): The FDA approval of etanercept in 1998 as the first tumor necrosis factor (TNF) inhibitor for rheumatoid arthritis opened the biologic therapy era, fundamentally altering treatment trajectories. Subsequent approvals — including rituximab, abatacept, and the JAK inhibitor class — created an entirely new pharmacological domain requiring specialized prescribing competency.
Subspecialization (2000s–present): Formal fellowships in pediatric rheumatology and credentialing pathways for musculoskeletal ultrasound certification represent the most recent phase of specialty differentiation.

Common scenarios

The historical trajectory of rheumatology surfaces in three recurring scenarios within clinical and regulatory practice.

Training pipeline recognition: Rheumatology fellowship programs are accredited through the Accreditation Council for Graduate Medical Education (ACGME), which requires a minimum of 24 months of subspecialty training following internal medicine residency. This accreditation structure was formalized decades after the specialty's clinical founding — the ACGME did not adopt its current program requirements framework until the 1980s — creating a lag between clinical practice and formal credentialing infrastructure that still shapes workforce distribution.

Classification criteria revisions: The ACR and EULAR jointly revised the classification criteria for rheumatoid arthritis in 2010, replacing the 1987 ACR criteria that had governed diagnosis for 23 years. This revision shifted the diagnostic framework from late-stage erosive disease to early inflammatory arthritis, reflecting advances in biomarker testing such as anti-CCP antibodies. Classification criteria revisions are consequential because they define patient populations in clinical trials, insurance coverage determinations, and epidemiological research.

FDA drug approval history: The regulatory history of biologic therapies and JAK inhibitors is inseparable from rheumatology's clinical evolution. The FDA's Arthritis Advisory Committee reviews new molecular entities for rheumatic indications, and the approval history of this drug class — spanning etanercept (1998) through the JAK inhibitor approvals of 2012–2022 — documents the specialty's pharmacological expansion in regulatory time.

Decision boundaries

Distinguishing rheumatology from adjacent specialties requires understanding the historical lines that were drawn as the field developed.

Rheumatology versus orthopedics: Orthopedic surgery addresses mechanical and structural joint disease — fractures, ligament tears, and degenerative joint replacement. Rheumatology addresses inflammatory, autoimmune, and metabolic joint disease. This distinction, now formalized in training requirements and board certification domains, was largely informal before the mid-twentieth century. The rheumatology-vs-orthopedics boundary became clinically significant as immunosuppressive therapies created management pathways that had no surgical equivalent.

Autoimmune versus non-inflammatory musculoskeletal disease: Fibromyalgia and osteoarthritis, both within rheumatology's scope, are not autoimmune or primarily inflammatory conditions. Their inclusion in the specialty reflects a historical aggregation of musculoskeletal conditions under one credentialing umbrella rather than a unified pathophysiological logic.

Pediatric versus adult rheumatology: Juvenile idiopathic arthritis and pediatric-onset lupus involve distinct disease patterns from their adult counterparts. The ABIM does not separately certify pediatric rheumatology — that credentialing pathway runs through the American Board of Pediatrics (ABP), which administers its own subspecialty examination, creating a formal jurisdictional boundary established in the 1990s.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)